Seagen-019 - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see how a combination of two experimental drugs, tucatinib and trastuzumab, work in your body and against your cancer.

What is the Condition Being Studied?

Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults age 18 or older who:
- Are diagnosed with non-squamous NSCLC with HER2 alterations

For more information about who can be in this study, please contact the study team.

Age Group
Adults

What is Involved?

This study has 2 parts: a screening period and a study dosing period.

If you join this study, during the screening period you will:
- Have blood draws
- Visit the clinic for various tests to see if you’re eligible for the dosing period

If you're eligible for the dosing period, you will:
- Have blood draws
- Have imaging scans (CT and MRI)
- Receive study drugs tucatinib and trastuzumab
-- Tucatinib is taken by mouth 2 times per day
-- Trastuzumab is given by IV once every 3 weeks

Study Details

Full Title
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00107057
NCT: NCT04579380
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698